Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Unraveling the web of nAMD: A transcriptomic analysis of age-related macular degeneration-associated cytokines in primary human retinal endothelial cells.

ABSTRACT: Neovascular age-related macular degeneration (nAMD) is a complex, blinding retinal disease underpinned by a dynamic and dysregulated interaction among pathogenic cytokines. The present study investigates the impact of six nAMD-associated cytokines, namely transforming growth factor-beta 1 and 2 (TGF-β1/2), tumour necrosis factor-alpha (TNF-α), thrombin, interleukin-6 (IL-6) and vascular endothelial growth factor (VEGF), on the transcriptome of primary human retinal endothelial cells (HRECs), both individually and as a collective 'cocktail'. HRECS were treated for 24 hours before being harvested for bulk RNA-seq. In performing this study, we have described the different transcriptomic signatures of each cytokine in driving nAMD-associated inflammatory, angiogenic and fibrotic pathways when presented in isolation to primary HRECs. Additionally, this study dissects a novel 'cocktail’ effect in the collective group characterised by further differential expression of genes, some of which were not induced by any of the individual cytokines. We explore the translatability of our study as an in vitro model of nAMD in endothelial cells by mapping the identified differential expression patterns to marker gene sets identified in previously performed scRNASeq of nAMD-affected human donor eyes.

ORGANISM(S): Homo sapiens

PROVIDER: GSE270418 | GEO | 2025/12/30

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Dimethyl Fumarate (DMFu) as an anti-angiogenic agent in VEGF-treated human microvascular retinal endothelial cells (HRECs).

Project description:Vascular endothelial growth factor (VEGF) is a key driver of retinal and choroidal angiogenesis in wet age-related macular degeneration (nAMD). The present study investigated the impact of dimethyl fumarate (DMFu), a novel nAMD therapeutic candidate, on the transcriptomic profile of VEGF-treated primary human retinal endothelial cells (HRECs). In performing this study, we have described the individual transcriptomic implications of VEGF and DMFu in HRECs and characterised the impact of DMFu treatment on gene expression in VEGF-activated HRECs.

2025-09-03 | GSE285562 | GEO

Tissue origin of endothelial cells determines immune system modulation and regulation of HIF1α-, TGFβ- and VEGF- signaling

Project description:Dysfunction of the blood retinal barriers and/or proliferation of retinal and choroidal endothelial cells are caused by late stages of diabetic retinopathy (DR) and neovascular age-related macular degeneration (nAMD). To elucidate endothelial-derived pathomechanisms in DR and nAMD, we established immortalized mouse cell lines of retinal (REC), choroidal (ChEC) and brain (BEC)endothelial cells. We compared the functional and transcriptomic state of these cells depending on their tissue origin. Intriguingly, activation of the wingless-type MMTV integration site (Wnt)/β-catenin signaling pathway restored barrier properties in BEC and REC, but increased permeability of ChEC. Transcriptome profiling showed that the immune system and pathways such as hypoxia-inducible factor (HIF) 1/2α-, transforming growth factor (TGF) β- and vascular endothelial growth factor (VEGF) were differentially regulated among endothelial cells. These findings significantly increase the understanding of the vascular biology of endothelial cells, highlighting the fact that depending on their tissue origin, their contribution to vascular pathologies such as DR or nAMD may vary.

2024-12-05 | GSE254272 | GEO

Placental Growth Factor Regulates the Pentose Phosphate Pathway and Antioxidant Defense Systems in Human Retinal Endothelial Cells

Project description:The molecular mechanisms whereby placental growth factor (PlGF) mediates its effects in nonproliferative diabetic retinopathy (DR) are unknown. To better understand the role of PlGF in DR, we used tandem mass tags (TMT)-labeled quantitative proteomics to human retinal endothelial cells (HRECs), treated anti-PlGF antibody as a experimental, PBS as a control.

2020-03-17 | PXD017195 | Pride

Unraveling the web of nAMD: A transcriptomic analysis of age-related macular degeneration-associated cytokines in primary human retinal endothelial cells.

Project description:Unraveling the web of nAMD: A transcriptomic analysis of age-related macular degeneration-associated cytokines in primary human retinal endothelial cells.

| PRJNA1126598 | ENA

Activin A prevents hyper-responsiveness to VEGF in pathological blood vessels by perturbing trafficking of activated VEGFR2

Project description:While quality of life compromising afflictions such as diabetic retinopathy (DR) are driven by vascular endothelial growth factor (VEGF), there is a growing appreciation that the concentration of VEGF is not the only influencer of vascular dysfunction within the retina. Activin A (activin), a ligand of the transforming growth factor β superfamily (TGF-β), attenuated VEGF-induced VE-cadherin disorganization, pore formation and permeability of primary human retinal endothelial cells (HRECs). Efforts to further investigate the mechanism of this phenomenon revealed that activin reduced expression of Rab11, which was required for the activin effect. The activin effect was not observed in cells with suppressed expression of the endosomally-localized protein tyrosine phosphatase, (PTP1b), whereas PTPs present on the plasma membrane were dispensable. Activin attenuated VEGF-mediated phosphorylation of VEGF receptor 2 (VEGFR2) at time points 30 min and longer post stimulation. Together these data support the concept that activin suppressed VEGF-induced barrier relaxation by perturbing trafficking of activated VEGFR2. This activin-based suppression of responsiveness to VEGF was compromised in the endothelium of pathological blood vessels from patients who developed end-stage proliferative diabetic retinopathy (PDR). This defect rendered HRECs hyper-responsive to VEGF and was not observed in retinal vessels of diabetic mice, which do not develop the angiogenic forms of DR. These data provide novel insights regarding the pathogenesis of PDR in patients.

2025-06-03 | GSE291008 | GEO

CD11c+ macrophages are pro-angiogenic and necessary for experimental choroidal neovascularization

Project description:Patients with neovascular AMD (nAMD) suffer vision loss from destructive angiogenesis, termed choroidal neovascularization (CNV). Macrophages are found in CNV lesions from nAMD patients. Additionally, Ccr2-/- mice, which lack classical monocyte-derived macrophages, show reduced CNV size. However, macrophages are highly diverse cells that can perform multiple functions. We performed single-cell RNA-sequencing on immune cells from wildtype and Ccr2-/- eyes to uncover macrophage heterogeneity during the laser-induced CNV mouse model of nAMD. We identified 12 macrophage subtypes, including Spp1+ macrophages. Spp1+ macrophages were enriched from wildtype lasered eyes and expressed a pro-angiogenic transcriptome via multiple pathways, including vascular endothelial growth factor signaling, endothelial cell sprouting, cytokine signaling, and fibrosis. Additionally, Spp1+ macrophages expressed the marker CD11c, and CD11c+ macrophages were increased by laser and present in CNV lesions. Finally, CD11c+ macrophage depletion reduced CNV size by 40%. These findings broaden our understanding of ocular macrophage heterogeneity and implicate CD11c+ macrophages as a potential therapeutic target for treatment-resistant nAMD patients.

2023-02-27 | GSE222094 | GEO

Molecular biomarkers of neovascular age-related macular degeneration with incomplete response to anti-vascular endothelial growth factor treatment

Project description:The standard treatment for neovascular age-related macular degeneration (nAMD) consists of intravitreal anti-vascular endothelial growth factors (VEGF). However, for some patients, even maximal anti-VEGF treatment does notentirely suppress exudative activity. The goal of this study was to identify molecular biomarkers in nAMD with incomplete response to anti-VEGF treatment. Aqueous humor (AH) samples were collected from three groups of patients: 18 patients with nAMD responding incompletely to anti-VEGF, 19 patients affected by nAMD with normal treatment response, and 14 control patients without any retinopathy. Proteomic and multiplex analyses were performed on these samples. Proteomic analyses showed that nAMD patients with incomplete anti-VEGF response displayed an increased inflammatory response, complement activation, cytolysis, protein-lipid complex, and vasculature development pathways. Multiplex analyses revealed a significant increase of soluble vascular cell adhesion molecule-1 (sVCAM-1) [p=0.001], interleukin-6 (IL-6) [p=0.009], bioactive interleukin-12 (IL-12p40) [p=0.03], plasminogen activator inhibitor type 1 (PAI-1) [p=0.004], and hepatocyte growth factor (HGF)[p=0.004] levels in incomplete responders in comparison to normal treatment response. Interestingly, The same biomarkers showed a high intercorrelation with r2 values between 0.58 and 0.94. In addition, we confirmed by AlphaLISA the increase of sVCAM-1 [p<0.0001] and IL-6 [p=0.043] in incomplete responder group. Incomplete responders in nAMD are associated with activated angiogenic and inflammatory pathways. The residual exudative activity of nAMD despite maximal anti-VEGF treatment may be related to both angiogenic and inflammatory responses requiring specific adjuvant therapy.

2021-01-18 | PXD022471 | Pride

Transcriptome profiling identified a 3-lncRNA regulatory network in transthyretin against glucose induced hRECs dysfunction

Project description:Transcriptome of human retinal endothelial cells (hRECs) treated with low glucose (LG), high glucose (HG) or high glucose with 4 uM TTR (HG+TTR) were conducted. Differentially expressed lncRNAs, mRNAs and TTR related lncRNAs and mRNA were acquired for further analysis. Functional annotation and enrichment including KEGG pathway, GO and GSEA were applied to analyze TTR regulated pathway and process. WGCNA analysis was implemented to obtain hub modules and genes. LncRNA-mRNA regulatory network were constructed based on cis, trans and ceRNA acting mode.

2018-07-18 | GSE117238 | GEO

Analyses of long non-coding RNAs in human retinal endothelial cells following glucose treatment

Project description:The differential expression of lncRNAs in human retinal endothelial cells (HRECs) was investigated with a commericially available microarray (ArrayStar Human LncRNA Microarray V3.0; ArrayStar Inc., Rockville, Maryland USA). Approximately 28,035 lncRNAs and 21,407 coding transcripts were detected using this microarray. In addition to the array findings, lncRNAs were further constructured using transcriptome databases (including RefSeq, Gencode, UCSC). Sequences were selected using proprietary strategies and each transcript is represented by a specific exon or splice junction probe, which can accurately identify an individual transcript. Nevertheless, both postive and negative probes for housekeeping genes were additionally used as controls.

2018-11-06 | GSE122189 | GEO

Integrated Proteomic Profiling of Aqueous Humor Reveals CDC42/RHOA-Mediated Pathogenic Mechanisms in nAMD and PDR

Project description:Neovascular AMD (nAMD) and proliferative diabetic retinopathy (PDR) are major blinding retinal diseases characterized by pathological angiogenesis. Using data-independent acquisition (DIA) proteomics, we analyzed aqueous humor from nAMD, PDR, and cataract control patients. Among 3186 identified proteins, 877 (nAMD) and 1017 (PDR) differentially expressed proteins (DEPs) were detected. Functional enrichment highlighted inflammatory and metabolic pathway dysregulation in both diseases. CDC42 and RHOA were consistently upregulated and implicated in cytoskeletal remodeling and angiogenesis. This study reveals shared molecular mechanisms in nAMD and PDR, proposing new targets for therapeutic intervention.

2025-09-09 | PXD068217 |